An observational study in Stage IV Non-small Cell Lung Cancer, Stage IV Malignant Melanoma and Stage IV Small Cell Lung Cancer, sponsored by OncoHost Ltd.. Active, not recruiting at 41 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-15.
Sponsored by OncoHost Ltd. · Observational
The PROPHETIC study is a prospective, multi-center, international clinical study aimed at developing an algorithm to predict patient outcomes. The study involves analyzing the proteomic profiles of patients undergoing therapy to assess the likelihood of clinical benefit from their prescribed treatment. Blood samples are collected prior to and during the treatment period and analyzed as part of the ongoing development of thealgorithm.
The goal of this research study is to develop an algorithm that predicts the patient's treatment outcome.This algorithm will serve as a tool for physicians when making treatment decisions, specifically for stage IV NSCLC and malignant melanoma patients receiving anti-cancer treatments. The investigators also aim to identify the metabolic pathways that could lead to better therapeutic options. The patients will be given their treatment according to the institute's standard of care. The patients will provide two blood samples and clinical data will be collected from their medical records.
In the first part of the trial, the data obtained from the blood samples and the medical records of the patients will be used to develop the prediction algorithm, and in the second part of the trial, the algorithm will be validated by comparing the objective response rate of the patients to the theoretical response prediction of the algorithm.
6,488 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,632 are open to participants now.
This study's planned enrollment of 10,000 is above the median of 161 across 949 observational studies indexed under Carcinoma, Non-Small-Cell Lung.
Browse Carcinoma, Non-Small-Cell Lung studies →OncoHost Ltd. is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Normal hematologic, renal and liver function:
Exclusion Criteria:
Stage IV NSCLC patients treated with ICI or a combination of ICI and chemotherapy in any line of treatment, or with chemotherapy as a first line treatment.
Other: Plasma sample collection
Patients with Stage III unresectable NSCLC treated with ICI therapy or ICI in combination with chemotherapy
Other: Plasma sample collection
Stage IV malignant melanoma patients treated with any regimen that includes ICI therapy as a monotherapy or in combination with targeted therapy in any line of treatment. In specific sites, Stage IV melanoma patients treated with targeted therapy (as a reference population).
Other: Plasma sample collection
Stage IIIb-d malignant melanoma patients treated with any regimen that includes ICI therapy as monotherapy or in combination with targeted therapy as adjuvant therapy.
Other: Plasma sample collection
Stage IV SCLC patients treated with any regimen of ICI, chemotherapy or combination of ICI and chemotherapy in any line of treatment.
Other: Plasma sample collection
Collect at least two plasma samples
Measured biological features at baseline (pre-treatment) and after 1st dose administration (on-treatment) and during treatment (optional)
Biological features are analyzed in biological samples taken from the patients as part of the study
Time frame: Measured biological features are analyzed in samples taken at baseline (prior treatment) and after the 1st dose administration (on-treatment) and during treatment (optional)
Overall response as determined by RECIST 1.1 or any other validated clinical scales for response, every 3 months or according to the standard of care
Overall response as determined by RECIST 1.1 or any other validated clinical scales for response, every 3 months or according to the standard of care
Time frame: Every 3 months or according to the standard of care
Progression Free Survival (PFS)
Collect Progression Free Survival (PFS) dates
Time frame: At progression during treatment
Overall survival or last follow-up
Collect overall survival or last follow-up dates
Time frame: Overall survival or last follow-up
Adverse Events (AE)
AE to treatment, as reported by the patient
Time frame: Adverse events (AE) during treatment and until the end of study
Plan to share: Undecided
This study is active, not recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Non-Small-Cell Lung→
OncoHost Ltd.